November 16, 2018
There is confusion as the focus is short-term with some or none near or long-term expectation
Risk is not always diminished as time rolls forward
There is just too much fluctuation and investors get tired and more skeptical of risk adjusted prognoses
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!
A trusted source of factual reporting!
November 16, 2018
Q3/18 financial results is a scorecard of (AKA) earnings of 45 covered companies
37 of 45 by 11/16The current LPS (loss per share) or net income, cash positio, "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"
Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
November 16, 2018
The tug-of-war of volatility with strong moves to the upside and weakness to the down
Interesting volume stat: 7 out of 28 of the upside had higher (than the 3 month average) volume and 3 out of the 14 downside experienced greater volume (than the 3 month average).
Who is defining the metrics for investors?
Some have stated, “I am the “weatherman” of the sector; forecasting and presenting conditions of the sector in a given period.”
November 16, 2018
Q3/18 financial results is a scorecard of (AKA) earnings of 45 covered companies 37 of 45 by 11/16 The current LPS (loss per share) or net income, cash positio, "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status" Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
November 9, 2018
Post reporting their Q’s; snapshots of LPS (loss-per-share) and net incomes - follow the bouncing share prices … A breakdown of reporting “figures” and commentary including Thursday’s closing numbers,: Adverum Biotechnologies (ADVM +$0.05), Histogenics (HSGX +$0.01), BioTime (NTSEMKT: BTX -$0.11), Applied Genetic Technologies (AGTC +$0.21), Intrexon (XON -$0.12), BioLife Solutions (BLFS +$0.16), Caladrius Bioscience (CLBS +$0.32), Pluristem (PSTI -$0.01), Sangamo Therapeutics (SGMO -$0.58), Stemline Therapeutics (STML -$0.36), Organovo Holdings (ONVO) and Biostage (BSTG -$0.10) Ben Graham used to talk about the stock market being a cross between a voting machine and a weighing machine The market is still voting on Friday ...
November 8, 2018
Post Wednesday’s Q3/18 reporting – there are more downs and a few ups; ALNY (-$3.27), CRSP (-$0.37), EDIT (+1.26), OSIR (+$0.45, RGNX (-$4.57), SAGE (+$2.71, VYGR (-$1.92), VSTM (-$0.03) and EDIT (+$1.31) In the midst of a market rally, there is still pain … During “earning’s” season, traders vote by buying and selling shares, and in the short run; the trades are motivated by those meeting “street” expectation versus LPS (loss-per-share) as compared to net income.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
November 16, 2018
RegMed Investors’ (RMi) closing bell: volume is and isn’t the determinant
November 16, 2018
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
November 16, 2018
RegMed Investors’ (RMi) pre-open: enduring a bumpy market path
November 15, 2018
RegMed Investors’ (RMi) closing bell: rolling thunder of pricing after the session’s spits and spurts
November 15, 2018
RegMed Investors’ (RMi) pre-open: correction needed
November 14, 2018
RegMed Investors’ (RMi) closing bell: selling pressure that began in September continues
November 14, 2018
RegMed Investors’ (RMi) pre-open: the wolves of share pricing are pacing the herd
November 13, 2018
RegMed Investors’ (RMi) closing bell: the value of banking, influence, information and access
November 13, 2018
RegMed Investors’ (RMi) pre-open: I’ve been down too much; I’ve forgotten how to stay up
November 12, 2018
RegMed Investors’ (RMi) closing bell: a severely wounded sector in the trenches of the overbought and oversold
November 12, 2018
RegMed Investors’ (RMi) pre-open: sentiment resides in trading
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
